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Compounds containing cyanoguanidine and 3-amino-1,2,4-5 
benzothiadiazine-1,1-dioxide have been studied as anion 
receptors and transporters. Significant affinity for oxo-anions 
was observed in organic solution and the receptors were 
found to function as transmembrane chloride/nitrate 
antiporters with transport rates enhanced in the presence of 10 
valinomycin – K+ complex. 
The transport of anions across lipid bilayers is vital to a number 
of important biological processes. Dysregulation of passive 
chloride transport causes a number of diseases including cystic 
fibrosis. There is therefore intense current interest in developing 15 
synthetic transmembrane transporters to act as potential future 
therapeutic substitutes for naturally occurring ion channels (and 
as tools for the study of anion transport processes in cells).1 
Recent work within our group has highlighted the anion transport 
capabilities of a variety of molecules2 including a series of simple 20 
thioureas.3,4 However, some thiocarbamates and thioureas have 
been found to be toxic,5 with the mechanism of toxicity not fully 
understood.6 Non-classical isosteres such as substituted guanidine 
ligands 1 and 2, offer a promising non-toxic alternative to 
thioureas. In particular cyanoguanidine has comparable physical 25 
properties to thiourea (e.g. pKa: 15 (thiourea) and 14 
(cyanoguanidine); hydrophobic partition P: 0.09 (thiourea) and 
0.07 (cyanoguanidine); C-N bond lengths: 1.34 Å both thiourea 
and cyanoguanidine; N-C-N angle: 119˚ (thiourea) and 124˚ 
(cyanoguanidine), respectively) and is present in the drug 30 
cimetidine.7 However, N,N’,N’’-trisubstituted guanidine groups 
often adopt a trans orientation of the two hydrogen atoms of the 
guanidine subunit and hence are not preorganised to bind anionic 
guests (Fig. 1).8 Alternative conformationally locked systems 
containing parallel hydrogen bond donors based upon 3-amino-35 
1,2,4-benzothiadiazine-1,1-dioxide (e.g. 3). These groups have 
been synthesised previously9 but have not yet applied to anion 
recognition. As both cyanoguanidines and derivatives of 3-
amino-1,2,4-benzothiadiazine-1,1-dioxide are known to be 
compatible with biological systems7,9-11 we decided to synthesise  40 
some potential anion receptors 1-3 containing these groups and 
study their lipid bilayer transport properties compared to simple 
thiourea 4. 
The receptors 1-4 were synthesised by modifications to literature 
procedures (see ESI†).4,11,12 Crystal structures of the both 45 
cyanoguanidine receptors 1 and 2 show the compounds adopt the 
trans orientation of the two hydrogen atoms of the guanidine 
subunit in the solid state (Fig. 1a and Fig. 1b). Strong 
intermolecular alternating N-H···N hydrogen bonds (N···N 
distances of 2.932(4) and 2.950(4) Å in 1 and 2.857(3) Å in 2, 50 
respectively, Table S1 ESI†) between the cyanoguanidine C≡N- 
group and the cis-orientated N-H group of two ligands support 
the present arrangement. In addition weaker N-H···N hydrogen 
bonds (N···N distance of 3.122(3) and 3.127(3) Å in 1 and 
3.013(3) Å in 2, respectively) are formed between the 55 
cyanoguanidine C≡N- group and the trans-orientated N-H group 
to link the dimer. This results in 2-D network of hydrogen bonds 
in the crystal. In contradistinction to these results, the cis-
orientation is observed for the thiourea group in the crystal 
structure of 4 (Fig. S1 ESI†).  60 
Fig. 1 Schematic draw of the crystal structure (a) of 1 and (b) of 
2, selected atom labels, dotted lines represent hydrogen bonds, 
non-interacting hydrogen atoms omitted for clarity, for 2 major 
occupied species only, Symmetry codes: i = 1+x,y,z; ii = 
1/2+x,3/2-y,-z; iii = -1/2+x,1/2-y,-z; iv = 2-x,1-y,1-z; v = -2-x,-65 
1/2+y,1/2-z; vi = 2-x,-1/2+y,1/2-z. 
 
 Proton NMR titration techniques were used to measure the 
stability of the receptor : anion complexes. Job plot analyses 
indicate a 1:1 binding mode for all the receptors (see ESI†). 70 
Stability constants for the formed complexes were determined 
using the EQNMR computer program.13 Proton NMR titrations 
were conducted in DMSO-d6/0.5 % water solutions with 
tetrabutylammonium anion salts. The results show that in all 
cases the receptors bind sulfate strongly with log Ka of 3.59 and 75 
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3.62 for receptor 1 and 4 and log Ka, > 4 for receptors 2 and 3. 
Stability constants with chloride, dihydrogen phosphate, benzoate 
and acetate were also determined (Table 1). Addition of 
tetrabutylammonium nitrate under these conditions did not cause 
a shift of the receptors’ proton resonances. 5 
 Detailed examinations of the titration spectra of receptor 1 
show a significant difference in the NH-proton shift upon the 
titration with sulfate and chloride (Fig. 2). The stack plot shows 
the simultaneous shift of the NH resonances by 3.3 and 3.5 ppm 
upon the addition of sulfate. This is evidence that leads us to 10 
suggest that the receptor is conformationally flexible in solution 
and in the presence of sulfate both NH groups are oriented 
towards the anion. On the other hand, the weaker binding of 
chloride results in a significant shift of only one proton signal by 
0.3 ppm in the presence of excess chloride, evidence to suggest 15 
that anion interacts with only a single NH group in this case. 
 
Table 1 Stability constants log K of 1:1 complexes in DMSO-d6/H2O 0.5 
%, 25 °C. Errors are estimated to be < 15 %.  
anion 1 2 3 4 
SO42- 3.59 > 4 > 4 3.61a) 
H2PO4- 2.37 -b) 3.74 2.42 
Cl- 0.56a) -c) 1.56 -c) 
PhCOO- 2.03 -b) 3.70 2.32 
CH3COO- 2.51 3.23 3.91 2.64 
a) error 20 % b) broadened NMR resonances, c) small shifts – could not 20 
be fitted to a 1:1 or 1:2 binding model  
 
 
Fig. 2 NMR titrations of compound 1 with a) TBA2·SO4 (top) and b) 
TBA·Cl (bottom).  25 
 
In order to study the chloride transport properties of compounds 
1–3 and the control compound 4 we prepared a series of 
unilamellar 1-palmitoyl-2-oleoylphosphatidylcholine (POPC) 
vesicles loaded with KCl (489 mM) and suspended them in an 30 
external KNO3 (489 mM) solution using previously reported 
procedures.6,7 A sample of receptor 1-4 (2 % molar carrier to 
lipid) was added as a DMSO solution and the resultant Cl- efflux 
monitored using a chloride selective electrode. After 300 s, the 
vesicles were lysed by addition of detergent and the final reading 35 
of the electrode was used to calibrate 100 % release of chloride. 
The results are shown in Fig. 3 and reveal chloride transport of 
compounds 1 and 3 (both 5 % after 270 s). The pentafluorophenyl 
substituted receptor 2 was found to be more active and 
approaching 29 % release of chloride over the timescale of the 40 
experiment. This is comparable to the transport ability of the 
thiourea receptor 4. The latter shows a chloride efflux of 
approximately 30 %, which is similar to the activity of a 
previously reported phenyl thiourea receptor.4 
There are a number of potential mechanisms that could be 45 
responsible for releasing chloride under the conditions of the 
experiment. We repeated the transport experiments with sodium 
rather than potassium salts and found no change in the chloride 
transport rate (evidence against a K+/Cl- co-transport mechanism). 
The transport experiments were repeated under similar conditions 50 
but with sulfate as the extravesicular anion.  Under these 
conditions no chloride transport was observed. This is evidence 
that leads us to suggest that Cl-/NO3- antiport is the predominant 
mechanism responsible for the release of chloride from the 
vesicles. Further studies in POPC/cholesterol 70 : 30 vesicles 55 
showed a reduction in chloride transport rate consistent with the 
compounds 1-4 functioning as discrete molecular carriers and not 
as channels (Fig. S2 – S5 ESI†).  
 
 60 
Fig. 3 Chloride efflux promoted by 0.02 molar equiv. of receptors 1-4 
from unilamellar POPC vesicles loaded with 489 mM KCl buffered to pH 
7.2 with sodium phosphate salts. The vesicles were dispersed in 489 mM 
KNO3 buffered to pH 7.2 with 5 mM sodium phosphate salts. At the end 
of the experiment, detergent was added to lyse the vesicles and calibrate 65 
the ISE to 100 % chloride release. Each point represents the average of 
three trials.   
We then repeated these experiments in the presence of the 
potassium ionophore valinomycin. The same experimental 
conditions were used, namely KCl (489 mM) loaded vesicles 70 
suspended in an external KNO3 (489 mM) solution. The results 
are shown in Fig. 4 and reveal an enhancement in chloride 
transport when both valinomycin and one of the receptors 1-4 is 
present. For example a total chloride efflux of 58 % was observed 
for 2 and valinomycin present together compared to 29 % and 5 75 
% in the presence of either receptor alone in the previous 
experiment. A similar result was obtained with compound 4, 
namely an enhancement from 30 % in absence of valinomycin to 
56 % in the present of both, 4 and valinomycin. The chloride 
transport for 1 and 3 is increased from 5 % to 23 % if 80 
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valinomycin is added in an equimolar amount. The chloride 
efflux for the receptors 1-4 at 270 s in the absence and presence 
of valinomycin are given in Table 2. As no potassium gradient is 
present, the enhancement observed may be caused by the 
presence of valinomycin bound potassium cations in the 5 
membrane possibly either enhancing extraction of the anions 
from the aqueous phase into the membrane or stabilizing the 
receptor bound anion complexes in the lipid bilayer. 
 
Fig. 4 Chloride efflux promoted by 0.02 molar equiv. of receptors 1-4 in 10 
the presence and absence of valinomycin (0.02 molar equiv.) from 
unilamellar POPC vesicles loaded with 489 mM KCl buffered to pH 7.2 
with sodium phosphate salts. The vesicles were dispersed in 489 mM 
KNO3 buffered to pH 7.2 with 5 mM sodium phosphate salts. At the end 
of the experiment, detergent was added to lyse the vesicles and calibrate 15 
the ISE to 100 % chloride release. Each point represents the average of 
three trials. 
Table 2 Chloride efflux (%) promoted by 0.02 molar equiv. of receptors 
1–4 in the absence and presence of valinomycin (0.02 molar equiv.) from 
unilamellar POPC vesicles loaded with 489 mM KCl buffered to pH 7.2 20 
with sodium phosphate salts after 270 s. The vesicles were dispersed in 
489mM KNO3 buffered to pH 7.2 with 5 mM sodium phosphate salts. 
 Chloride efflux at 270 s (%) 
 1 2 3 4 
Absence of valinomycin 5 29 5 30 
Presence of valinomycin 23 58 23 56 
Conclusions 
This work has demonstrated that thiourea isosteres such as 
functionalised cyanoguanidines and the hexyl derivative of 3-25 
amino-1,2,4-benzothiadiazine-1,1-dioxide are capable of binding 
and transporting anions.  Compound 2 shows transport activity 
which is similar to thiourea derivative 4 whilst the transport 
properties of all the compounds are enhanced in the presence of 
valinomycin-K+. These initial studies with simple systems 30 
suggest that these hydrogen-bonding motifs may be optimised for 
anion complexation and transport.  We are currently working to 
incorporate these new anion transport hydrogen bonding motifs 
into more efficient transporters for chloride and other anions. 
 35 
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2: Cystal data for C14H15N4F5, M = 334.30, monoclinic, a = 13.6862(9) Å, 
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